Charo Scott
About Charo Scott
Charo Scott is the Director of CMC Product Development at Bristol-Myers Squibb, with over 20 years of experience in the pharmaceutical and biotechnology industries.
Company
Charo Scott is currently working at Bristol-Myers Squibb as the Director, CMC Product Development. She has held multiple leadership roles at Bristol-Myers Squibb, contributing significantly to the company's biologics development. Previously, she worked at Merck and University College London, where she cultivated substantial experience in biochemical and chemical engineering.
Title
Charo Scott holds the title of Director, CMC Product Development at Bristol-Myers Squibb. She specializes in Chemistry, Manufacturing, and Controls (CMC) product development specifically for biologics. She has also held roles such as Associate Director, IDTL CMC Biologics, and Sr. Scientist at Bristol-Myers Squibb.
Education and Expertise
Charo Scott earned a PhD in Biochemical Engineering from University College London and a BS in Chemical Engineering from the University of California, Berkeley. She has over 20 years of experience in the pharmaceutical and biotechnology industries, with a specialized focus on biologics. Her educational background and extensive industry experience provide a strong foundation for her expertise in CMC product development, regulatory submissions, and compliance.
Work Background
Charo Scott has a robust work background in the pharmaceutical industry. She held several key roles at Bristol-Myers Squibb since 2013, including Director, CMC Product Development, Associate Director, IDTL CMC Biologics, and Sr. Scientist. Before that, she was a Senior Research Biochemical Engineer and Research Biochemical Engineer at Merck from 2000 to 2013. Her career began as a PhD candidate in Biochemical Engineering at University College London from 2004 to 2008.
Achievements
Charo Scott has a proven track record of leading cross-functional teams in the pharmaceutical industry and has contributed to the development of several key biologic products at Bristol-Myers Squibb. She has been involved in the scale-up and commercialization of biologic products and has extensive experience in regulatory submissions and compliance. Her work focuses on overcoming the complexities and challenges of biologic product development.